If you’ve ever tried to outpace a failing heart with a stopwatch and a salt shaker, welcome to the absurdity that is acute decompensated heart failure treatment in 2025. The status quo is basically betting kidneys on a guess, and calling it standard of care. But now Reprieve Cardiovascular just closed a $61M Series B and rolled in with something a little more intelligent than guesswork: real-time, closed-loop, automated decongestion management.
This isn’t just another medtech startup tossing buzzwords around a PowerPoint. Reprieve Cardiovascular is going full Rain Man on fluid therapy, think sensors, real-time urine output tracking, personalized diuretic dosing, and saline infusion all synced through a bedside console with cloud brains. Precision. Speed. Safety. And yeah, kidneys that don’t just roll the dice and hope for the best.
The Series B was led by Deerfield Management, joined by Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, Cadence Capital, and a strategic investor who decided to stay coy. That’s a stack of firms that don’t throw money at pipe dreams, they invest where the tech is as sharp as the team. CEO Mark Pacyna, COO Tony Fields, and CFO Adam Bartnik are running point, and they’re not here to build prototypes, they’re building a platform that hospitals will actually use.
The science is catching up to the suffering. Reprieve just kicked off enrollment in the FASTR II pivotal trial at Washington University School of Medicine, with Baylor Scott & White Research Institute’s Dr. Javed Butler running the global PI play. They’re looking at 400 patients across North America and Europe, aiming to prove what early results already hinted at: twice the decongestion speed, no added renal drama.
Let’s not pretend this is just about clever tech. The market is $5-8B deep, and the human cost of inaction is even bigger, over 25 million global patients, average stays over five days, readmission rates that look more like boomerangs than discharges. This isn’t about disruption, it’s about delivering. And Reprieve Cardiovascular isn’t selling dreams. They’re selling outcomes, wrapped in an interface hospitals can integrate without a six-month consulting contract.
Reprieve’s tech is finally catching up to the biology. And this Series B? It’s not just a milestone. It’s the prelude to a new standard, real precision for real patients, in real time.
Not every startup can claim it’s fixing the plumbing of modern medicine. But then again, not every startup is Reprieve Cardiovascular.
